Skip to main content
Top
Published in: Supportive Care in Cancer 8/2013

01-08-2013 | Original Article

The poor use of methadone in Italian hospices

Authors: Sebastiano Mercadante, Alessandro Valle, Cristina Agnelotti, Amanda Caruselli

Published in: Supportive Care in Cancer | Issue 8/2013

Login to get access

Abstract

Purpose

A hospice may provide an ideal setting to use methadone because of a more protective environment in comparison with a home care setting, where it is seldom used. The aim of this survey was to investigate the frequency of the use of methadone in Italian hospices and how it is used.

Methods

The Italian registry of palliative care institutions, named Osservatorio Federazione cure palliative, was consulted at its official website. Phone interviews were planned with physicians who were delegated to provide the answers. Data regarding the hospice and experience of physicians were collected. Questions regarding the attitudes in using methadone were posed, including the frequency of use and how this drug was used.

Results

Of 165 centers contacted, information was available for 138 hospices (83.6 %). The majority of interviewed physicians considered methadone as a difficult drug to use, and only 38 responders (27.5 %) were using methadone as an analgesic in a minority of patients (less than 5 % in more than half of responders). When methadone is used as first opioid, all the patients receive less than 10 mg/day. Almost all physicians switched from morphine to methadone and used a conversion ratio inversely proportional to the morphine dose.

Conclusions

Physicians working in hospices should improve the knowledge regarding the use of opioids, including methadone, as well as complex treatments which can be the principal reason for hospice admission.
Literature
1.
go back to reference Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef Bruera E, Pereira J, Watanabe S, Belzile M, Kuehn N, Hanson J (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRef
2.
go back to reference Bruera E, Palmer JL, Bosnjak S et al (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22:185–192PubMedCrossRef Bruera E, Palmer JL, Bosnjak S et al (2004) Methadone versus morphine as a first-line strong opioid for cancer pain: a randomized, double-blind study. J Clin Oncol 22:185–192PubMedCrossRef
3.
go back to reference Caraceni A, Hanks G, Kaasa S et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Use of opioid analgesic in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68PubMedCrossRef Caraceni A, Hanks G, Kaasa S et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Use of opioid analgesic in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58–e68PubMedCrossRef
4.
go back to reference Cherny NI, Baselga J, de Conno F, Radbruch l (2009) Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 21:615–626CrossRef Cherny NI, Baselga J, de Conno F, Radbruch l (2009) Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: a report from the ESMO/EAPC Opioid Policy Initiative. Ann Oncol 21:615–626CrossRef
5.
go back to reference Deandrea S, Montanari M, Moja L et al (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991PubMedCrossRef Deandrea S, Montanari M, Moja L et al (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985–1991PubMedCrossRef
6.
go back to reference Mercadante S, Ferrera P, Villari P et al (2009) Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 37:632–641PubMedCrossRef Mercadante S, Ferrera P, Villari P et al (2009) Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit. J Pain Symptom Manage 37:632–641PubMedCrossRef
7.
go back to reference Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504–515PubMedCrossRef Mercadante S, Caraceni A (2011) Conversion ratios for opioid switching in the treatment of cancer pain: a systematic review. Palliat Med 25:504–515PubMedCrossRef
8.
go back to reference Mercadante S, Ferrera P, Casuccio A (2011) Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin 27:2357–2360PubMedCrossRef Mercadante S, Ferrera P, Casuccio A (2011) Outcome of opioid switching 4 weeks after discharge from a palliative care unit. Curr Med Res Opin 27:2357–2360PubMedCrossRef
9.
go back to reference Mercadante S (2012) Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med 13:399–404PubMedCrossRef Mercadante S (2012) Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit. Pain Med 13:399–404PubMedCrossRef
10.
go back to reference Mercadante S, Valle A, Porzio G et al (2013) Opioid switching in patients with advanced cancer followed at home. A retrospective analysis J Pain Symptom Manage 45:298–304CrossRef Mercadante S, Valle A, Porzio G et al (2013) Opioid switching in patients with advanced cancer followed at home. A retrospective analysis J Pain Symptom Manage 45:298–304CrossRef
11.
go back to reference Mercadante S, Bruera E (2006) Opioid switching: a systematic and critical review. Cancer Treat Rev 32:304–315PubMedCrossRef Mercadante S, Bruera E (2006) Opioid switching: a systematic and critical review. Cancer Treat Rev 32:304–315PubMedCrossRef
12.
go back to reference Mercadante S, Villari P, Casuccio A (2011) An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer 19:979–983PubMedCrossRef Mercadante S, Villari P, Casuccio A (2011) An Italian survey on the attitudes in treating breakthrough cancer pain in hospice. Support Care Cancer 19:979–983PubMedCrossRef
13.
go back to reference Mercadante S, Valle A, Sabba S et al (2013) Pattern and characteristics of advanced cancer patients admitted to hospices in Italy. Support Care Cancer 21:935–9PubMedCrossRef Mercadante S, Valle A, Sabba S et al (2013) Pattern and characteristics of advanced cancer patients admitted to hospices in Italy. Support Care Cancer 21:935–9PubMedCrossRef
14.
go back to reference Mercadante S, Fulfaro F (2005) World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 16(Suppl 4):132–135 Mercadante S, Fulfaro F (2005) World Health Organization guidelines for cancer pain: a reappraisal. Ann Oncol 16(Suppl 4):132–135
15.
go back to reference Mercadante S, Vitrano V (2010) Palliative care in Italy: problem areas emerging from the literature. Minerva Anestesiol 76:1060–1071PubMed Mercadante S, Vitrano V (2010) Palliative care in Italy: problem areas emerging from the literature. Minerva Anestesiol 76:1060–1071PubMed
16.
go back to reference Mercadante S, Porzio G, Ferrera P et al (2008) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12:1040–1046PubMedCrossRef Mercadante S, Porzio G, Ferrera P et al (2008) Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain 12:1040–1046PubMedCrossRef
17.
go back to reference Pearsons HA, de la Cruz M, El Osta B et al (2010) Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 116:520–528CrossRef Pearsons HA, de la Cruz M, El Osta B et al (2010) Methadone initiation and rotation in the outpatient setting for patients with cancer pain. Cancer 116:520–528CrossRef
18.
go back to reference Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 199816:3216–3221 Ripamonti C, Groff L, Brunelli C, Polastri D, Stavrakis A, De Conno F (1998) Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol 199816:3216–3221
19.
go back to reference Ripamonti C, Bandieri E, Roila F (2011) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 22(Suppl 6):69–77 Ripamonti C, Bandieri E, Roila F (2011) Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol 22(Suppl 6):69–77
20.
go back to reference Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449PubMedCrossRef Van den Beuken-van Everdingen MHJ, De Rijke JM, Kessels AG et al (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437–1449PubMedCrossRef
21.
go back to reference Zucco F, Hospice in Italia, 2° rilevazione ufficiale (2010) SICP, Seragnoli, Floriani, Ministero della Salute Zucco F, Hospice in Italia, 2° rilevazione ufficiale (2010) SICP, Seragnoli, Floriani, Ministero della Salute
22.
go back to reference Weschules DJ, McMath JA, Gallagher R, Alt CJ, Knowlton CH (2003) Methadone and the hospice patient: prescribing trends in the home-care setting. Pain Med 4:269–276PubMedCrossRef Weschules DJ, McMath JA, Gallagher R, Alt CJ, Knowlton CH (2003) Methadone and the hospice patient: prescribing trends in the home-care setting. Pain Med 4:269–276PubMedCrossRef
Metadata
Title
The poor use of methadone in Italian hospices
Authors
Sebastiano Mercadante
Alessandro Valle
Cristina Agnelotti
Amanda Caruselli
Publication date
01-08-2013
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 8/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-013-1785-8

Other articles of this Issue 8/2013

Supportive Care in Cancer 8/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine